Obesity Microbiota Research Service
InquiryOverview of Gut Microbiota
There are more than 100 trillion microorganisms in the human gut, known as the gut microbiota, which outnumber the body's cells by a factor of ten. These microbial populations survive on undigested food, intestinal mucus, and shed epithelial cells, which are their main sources of nutrition. Through their complex metabolic processes, gut microbes synthesize a wide array of bioactive molecules, including short-chain fatty acids and essential vitamins, as well as compounds with anti-inflammatory, analgesic, and antioxidant properties. Conversely, they can also generate harmful substances such as neurotoxins, carcinogens, and immunotoxins. These microbial byproducts have the potential to enter the bloodstream, directly influence gene expression, and affect both immune responses and metabolic pathways in the host. Therefore, maintaining a well-balanced gut microbiota is crucial for sustaining metabolic health and energy balance. Disruptions to this microbial equilibrium can precipitate metabolic disorders and increase central appetite, which are contributing factors to obesity.
Unraveling The Secrets of Gut Microbiota and Obesity for A Healthier Tomorrow
Given the intricate and diverse nature of the gut microbiota, the precise mechanisms by which these microorganisms contribute to obesity remain a topic of ongoing investigation. At Protheragen, our research team offers comprehensive services to research the interplay between obesity and gut microbiota. By researching their relationship, we identify potential Targets for obesity treatment, thereby advancing anti-obesity therapies. Specifically, we assist clients in studying how gut microbiota contribute to obesity, either through direct interactions with gastrointestinal tract cells or through indirect pathways involving metabolites that affect distant organs. Our research team combines cutting-edge techniques in microbiome analysis, metabolomics, and systems biology to deliver actionable insights. We employ advanced sequencing technologies to profile gut microbiota composition and function and utilize metabolite profiling to understand how microbial metabolites influence host physiology. Our research is centered on identifying functionally significant microbial groups to detect pathogenic microbiota linked to obesity and on researching targeted microbiota management strategies for individuals affected by obesity.
Advanced Gut Microbiota Profiling in Obesity
Our research team conducts thorough research into the mechanisms by which gut microbiota contributes to the development of obesity. Our advanced gut microbiota profiling offers comprehensive insights into obesity research, addressing several key aspects: the influence of gut microbiota on energy absorption, fat storage, gastrointestinal function, satiety, the gut-brain axis, circadian rhythms, and gluconeogenesis. Our these analyses are designed to help clients understand the multifaceted role of gut microbiota in regulating the onset and progression of obesity.
Genetics Analysis Service of Microbiota in Obesity
The interaction between microbial and human physiologies significantly affects health and development, with genetic variation increasingly shown to influence gut microbiota composition and function. Therefore, we use a systems genetics approach to combine data on physical traits, molecular traits, and gut microbiota composition. Through various methods, such as genome-wide association studies (GWAS), we seek to derive meaningful genetic insights. Our researchers explore the role of microbiota in obesity through an examination of key areas, including the microbiota present in the placenta, amniotic fluid, umbilical cord blood, and meconium.
Effect Analysis of Dietary Components on the Gut Microbiota
Through effect analysis, we investigate the intricate ways in which various dietary components influence the gut microbiota. By delving into the ramifications of high-fat, high-carbohydrate, high-protein, and high-fiber diets, we elucidate their effects on microbial diversity and functionality. Furthermore, exploring the implications of calorie-restricted and ketogenic diets enhances our understanding of their roles in gut health and inflammatory responses. Analyzing the Mediterranean diet sheds light on how a well-balanced, nutrient-dense dietary regimen fosters the proliferation of beneficial microbial populations and promotes overall gut wellness. Our offerings encompass thorough assessments and tailored recommendations derived from these comprehensive analyses, aimed at optimizing gut health.
Workflow
Here is a general experimental workflow for our obesity microbiota research service.
- Preparation of Animal Models
We select a model organism that aligns with the research goals, commonly mice or rats. Then implement specific interventions to induce obesity in these models, such as administering high-fat diets, modifying environmental conditions, or employing genetic modifications to manifest obesity characteristics.
- Sample Collection
Our researchers either gather samples directly from our animal models or accept samples provided by clients for comprehensive analysis. A variety of samples are analyzed, encompassing feces, blood, and intestinal tissues.
- Sample Processing
Subsequently, process and preserve samples with meticulous care to maintain microbial viability and analytical precision. This generally involves cryopreservation or immediate processing to safeguard against microbial alterations.
- Microbiota Analysis
We conduct 16S rRNA gene sequencing and metagenomic sequencing to analyze the microbial composition, functionality, and their correlation with obesity, offering detailed insights into microbial community changes.
- Data Analysis
Various bioinformatics tools and statistical techniques are employed to interpret data, evaluating microbial functional capabilities and metabolic activities to uncover their roles in obesity and related mechanisms.
Anti-Obesity Therapy Development at Protheragen
Building upon the substantial findings of our obesity microbiota research service, we have extended our endeavors to the anti-obesity therapy development, specifically concentrating on the anti-obesity small molecule drug development and anti-obesity gene therapy development domains.
Anti-Obesity Small Molecule Drug Development
In the realm of anti-obesity small molecule drug development, we exploit the gut microbiota as a target for drug screening, engineering small molecules capable of modulating microbiota composition and enhancing metabolic function, with the objective of inducing weight loss and alleviating obesity-associated symptoms.
Anti-Obesity Gene Therapy Development
In anti-obesity gene therapydevelopment service, we employ gene editing technologies to precisely modulate gene expression associated with obesity, coupled with the regulatory influence of gut microbiota, in order to explore more enduring and efficacious therapeutic strategies.
Anti-Obesity Cell Therapy Development
Our anti-obesity cell therapy development uses specialized cells to regulate metabolism and decrease weight. We prepare and expand these cells for therapeutic use, and test their effectiveness in animals to ensure safety and efficacy.
Anti-Obesity Antibody Therapy Development
Our anti-obesity antibody therapy development aims to create antibodies that target key obesity-related proteins to regulate metabolism and weight. We design and produce these antibodies through advanced biotechnological methods to ensure high specificity and potency.
Anti-Obesity Tissue Engineering Therapy Development
We design and fabricate these tissues using bioengineering techniques, integrating them with the body's natural systems. Preclinical studies in animal models assess the safety and efficacy of these engineered tissues, paving the way for future clinical testing.
Anti-Obesity Nanotherapy Development
Our anti-obesity nanotherapy development involves creating nanocarriers that deliver targeted drugs to reduce fat accumulation and enhance metabolism. We engineer anoparticles for improved efficacy and minimal side effects.
Preclinical Studies of Anti-Obesity Therapeutics
Obesity Models
To begin with, we have established a range of diverse Obesity Models. These models not only replicate the physiological and pathological characteristics of human obesity but also incorporate various factors such as gender, age, and genetic predisposition that influence the progression of obesity. This provides a reliable experimental platform for evaluating the efficacy of anti-obesity interventions.
Pharmacodynamic Study of Anti-Obesity Therapeutics
Following this, we conduct pharmacodynamic studies of anti-obesity therapeutics. Through meticulous observation of the impact of candidate drugs on weight reduction, improvement of metabolic parameters, and alterations in adipose tissue, we gain deeper insights into their therapeutic mechanisms, yielding critical data to inform drug design enhancements.
Pharmacokinetic Study of Anti-Obesity Therapeutics
Concurrently, the pharmacokinetic study of anti-obesity therapeutics is an indispensable component. We meticulously analyze the absorption, distribution, metabolism, and excretion of drugs within animal models, assessing their bioavailability and half-life, to provide scientific basis for determining appropriate dosing regimens and dosages.
Bioanalysis of Anti-Obesity Therapeutics
Moreover, bioanalysis employs highly sensitive and specific analytical techniques to accurately quantify the concentration of drugs and their metabolites in biological samples. This provides precise data support for our pharmacodynamic and pharmacokinetic investigations. By evaluating the drug's propensity to elicit an immune response, we can identify possible adverse effects that may arise in clinical applications, thereby informing modifications in formulation or administration strategies.
Safety Assessment of Anti-Obesity Therapeutics
Last but certainly not least, we perform safety assessments of anti-obesity therapeutics. Through comprehensive toxicological evaluations, we assess the potential impacts of candidate drugs on critical organs, such as the cardiovascular system, liver, and kidneys, as well as potential risks to reproductive and genetic systems, thereby ensuring their safety.
Through rigorous preclinical validation, we ascertain that each therapy is underpinned by a solid scientific basis prior to its transition into clinical trials, thereby furnishing substantial evidence for future clinical implementations.
Publication Data
DOI: 10.3390/nu15102236
Journal: Nutrients
Published: 2023
IF: 4.8
Result: In this article, authors point out the contemporary challenge of obesity as a major public health crisis of the 21st century, and describe its intricate relationship with the gut microbiota. The authors underscore the multifaceted influence of the gut microbial ecosystem on obesity, elucidating how it modulates systemic inflammation, immune responses, and energy metabolism, as well as its impact on the gut-host interface. Besides, they describe metabolomics as a systematic method for examining low-molecular-weight metabolites involved in metabolic pathways, which provides insights into the interactions between host metabolism and gut microbiota. They also research the effects of diverse dietary interventions on gut microbiome composition and the metabolome. The effectiveness of specific dietary measures in helping obese people lose weight is backed by evidence, but there is no agreement on the best dietary plan for both the short and long term. Furthermore, the authors propose that profiling metabolites and analyzing gut microbiota composition may serve as effective indicators for managing obesity and help identify optimal nutritional interventions.
Applications
- Obesity microbiota research service can be used to develop tailored dietary recommendations based on microbiota profiles to assist in weight loss and metabolic health improvement.
- Obesity microbiota research service is useful for developing therapeutic strategies targeting microbiota, such as probiotics, prebiotics, or microbiota transplants, to alleviate obesity-related conditions.
- Obesity microbiota research service can be applied to researching how environmental factors (such as diet, antibiotic use, and lifestyle) affect microbiota and their role in obesity.
Advantages
- Our research team provides a range of microbiota colonization research options, including but not limited to Lachnospiraceae, Clostridiaceae, and Bacteroides.
- Our researchers master systems genetics methodologies to reveal how genetic variations influence gut microbiota composition and functionality, which is vital for understanding the intricate relationship between microbiota and obesity.
- We use diverse sequencing technologies such as 16S rRNA gene sequencing and metagenomic sequencing, combined with metabolite profiling, Protheragen delivers profound insights into the microbiota's impact on host physiology.
Frequently Asked Questions
What types of microbiota colonization research can we conduct?
- Lachnospiraceae Colonization Studies
- Clostridiaceae Colonization Studies
- Ruminococcaceae Colonization Studies
- Lactobacillus Colonization Studies
- Bacteroides Colonization Studies
- Bifidobacterium Colonization Studies
- Desulfovibrio Colonization Studies
- Enterobacteriaceae Colonization Studies
- Akkermansia Colonization Studies
What animal models can we develop?
What factors affect the gut microbiome?
- Diet
- Lifestyle
- Environment
Protheragen explores the link between gut microbiota and obesity and offers microbiota colonization studies to see how microbes influence obesity. Besides, we conduct advanced profiling and genetics analysis for detailed microbial insights. If you use these services to help you understand and manage obesity through microbiota research, contact us.
Reference
- Puljiz, Z.; et al. Obesity, gut microbiota, and metabolome: from pathophysiology to nutritional interventions. Nutrients. 2023, 15(10): 2236.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.